BCIQ Profiles

Company Profile Report

Abivax's ABX464 improves mucosal healing, Mayo Score in Phase IIa for UC

Abivax S.A. (Euronext:ABVX) said ABX464 improved mucosal healing rate (50% vs. 11%, p=0.03) and reduced partial (62% vs. 32%, p<0.02) and total Mayo Scores (53% vs. 37%, p<0.03)

Read the full 286 word article

How to gain access

Continue reading with a
two-week free trial.